查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2019821

發炎性腸道疾病治療市場：市場規模、佔有率、成長率、全球產業分析、按類型、應用和地區分類的考察以及未來預測（2026-2034年）

Inflammatory Bowel Disease Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

發炎性腸道疾病（IBD）治療市場的成長要素

受克隆氏症和潰瘍性大腸炎等慢性胃腸道疾病盛行率不斷上升的推動，全球發炎性腸道疾病（IBD）治療市場正穩步擴張。到2025年，該市場規模達到295.7億美元，預計2026年將成長至312.4億美元，到2034年將達到416.4億美元，預測期內年複合成長率（CAGR）為3.66%。北美地區憑藉其強大的醫療保健基礎設施和先進生物製藥的高滲透率，在2025年以41.01%的市場佔有率引領市場。

發炎性腸道疾病（IBD）影響全球超過0.3%的人口，使其成為一項重大的公共衛生挑戰。生活方式的改變、環境因素、遺傳易感性和免疫系統功能障礙等因素都導致了疾病盛行率的上升。已開發國家提高公眾意識、早期診斷以及有利的保險償付政策，推動對有效治療方案的需求。

市場趨勢

人們越來越關注前沿研究和個人化醫療。

單細胞RNA定序和質譜流式細胞儀等技術進步改變發炎性腸道疾病（IBD）的治療。這些技術加深了對疾病機制的理解，並加速了標靶治療和個人化治療方案的研發。研究機構和製藥公司之間日益密切的合作推動該領域的創新。

市場成長要素

發炎性腸道疾病率上升

克隆氏症和潰瘍性大腸炎患者數量的不斷增加是市場成長的主要促進因素。遺傳因素、生活方式的改變和環境因素都加劇了疾病負擔。此外，疾病認知度的提升和診斷能力的進步也促使接受治療的患者人數增加。

強大的治療藥物研發管線

製藥公司正積極投資研發，以拓展產品平臺。目前已有超過145項臨床試驗進行中，許多藥物已進入後期研發階段。生物製劑、TNF抑制劑、IL抑制劑和JAK抑制劑的日益普及，顯著改善了治療效果，並推動了市場擴張。

市場限制因素

治療費用高昂

市場面臨的主要挑戰之一是發炎性腸道疾病（IBD）治療高成本，尤其是生物製藥。每位患者的年度治療費用波動較大，限制了發展中地區患者的治療機會。此外，印度和中國等新興國家有限的保險償付機制也進一步限制了市場成長。

依市場區隔進行分析

疾病特異性

依疾病類型分類，市場可分為克隆氏症和潰瘍性大腸炎兩大類。預計到2026年，克隆氏症市場將佔據主導地位，市場佔有率將達到63.78%，這主要得益於全球患病率和治療率的不斷提高。潰瘍性大腸炎市場也在成長，這得益於新藥核准的增加和治療可及性的提高。

依給藥途徑

根據給藥途徑，市場可分為口服藥物和注射藥物。到2026年，注射藥物將佔據市場主導地位，市場佔有率高達77.58%，這主要歸功於注射用生物製藥的廣泛應用。口服藥物因其便捷易用而日益受到歡迎。

藥物類別

市場涵蓋TNF抑制劑、IL抑制劑、JAK抑制劑、抗整合素藥物、皮質類固醇等。預計到2026年，TNF抑制劑將憑藉其在誘導和維持緩解方面的高效性，以58.77%的市場佔有率佔據主導地位。 JAK抑制劑也因其起效迅速而日益受到歡迎。

依通路

依通路分類，市場分為醫院藥房和零售藥房。2026年，在健保政策和專業藥物管理需求的推動下，醫院藥局通路將主導市場，佔據95.36%的市場佔有率。

區域趨勢

北美洲

北美在2025年以 121.3億美元的市場規模引領市場，並預計在2026年達到 128.1億美元。該成長是由先進的生物製藥療法、有利的償付方案和疾病患病率上升所推動的。

歐洲

到2025年，歐洲的市場佔有率達到 96.9億美元，預計到2026年將達到 102.8億美元。該地區受益於強力的監管支持和創新治療方法的普及。

亞太地區

亞太地區到2025年達到 58.1億美元，預計到2026年將達到 61.2億美元。人們意識的提高、醫療保健基礎設施的改善以及藥品核准的增加推動該地區的成長。

拉丁美洲、中東和非洲

到2025年，拉丁美洲的醫療市場規模達到11.9億美元，中東和非洲達到7.6億美元。這兩個地區均呈現溫和成長，主要得益於醫療保健投資的增加和人們健康意識的提高。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 主要考察

  • 克隆氏症率：依主要國家分類（2025年）
  • 潰瘍性大腸炎盛行率：依主要國家/地區分類（2025年）
  • 發炎性腸道疾病的平均治療持續時間
  • 接受各種治療的患者統計：概述
  • 價格和利潤率分析
  • 新產品發布：依主要企業分類
  • 關鍵產業趨勢：企業合併、商業合作
  • 管道分析：依主要企業分類
  • 新冠疫情對市場的影響

第5章 全球發炎性腸道疾病治療市場分析：探討與預測（2021-2034年）

  • 市場分析、洞察與預測：依疾病適應症
    • 潰瘍性大腸炎
    • 克隆氏症
  • 市場分析、洞察與預測：依給藥途徑
    • 口服
    • 注射藥物
  • 市場分析、洞察與預測：依藥物類別分類
    • IL抑制劑
    • TNF抑制劑
    • 抗整合素
    • JAK抑制劑
    • 皮質類固醇
    • 基於阿斯匹靈的藥物
    • 其他
  • 市場分析、洞察與預測：依通路分類
    • 醫院藥房
    • 零售藥局和其他
  • 市場分析、洞察與預測：依地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美發炎性腸道疾病治療市場分析：探討與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章 歐洲發炎性腸道疾病治療市場分析：探討與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪地那維亞
    • 其他歐洲國家

第8章 亞太地區發炎性腸道疾病治療市場分析：洞察與預測（2021-2034）

  • 國家
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章 拉丁美洲發炎性腸道疾病治療市場分析：探討與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章 中東與非洲發炎性腸道疾病治療市場分析：探討與預測（2021-2034年）

  • 國家
    • 海灣合作理事會國家
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市場佔有率分析（2025年）
  • 公司簡介
    • Pfizer Inc.
    • CELLTRION INC.
    • Johnson & Johnson Services, Inc.
    • AbbVie Inc.
    • Takeda Pharmaceutical Company Limited
    • UCB SA
    • Bausch Health Companies Inc.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Gilead Sciences
    • EA Pharma Co., Ltd
Product Code: FBI106704

Growth Factors of inflammatory bowel disease (IBD) treatment Market

The global inflammatory bowel disease (IBD) treatment market is steadily expanding due to the rising prevalence of chronic gastrointestinal disorders such as Crohn's disease and ulcerative colitis. The market was valued at USD 29.57 billion in 2025 and is projected to grow to USD 31.24 billion in 2026, reaching USD 41.64 billion by 2034, exhibiting a CAGR of 3.66% during the forecast period. North America dominated the market with a 41.01% share in 2025, driven by strong healthcare infrastructure and high adoption of advanced biologics.

Inflammatory bowel disease affects over 0.3% of the global population, making it a significant healthcare concern. Factors such as lifestyle changes, environmental influences, genetic predisposition, and immune system dysfunction are contributing to the increasing incidence of these diseases. Growing awareness, early diagnosis, and favorable reimbursement policies in developed economies are boosting the demand for effective treatment solutions.

Market Trends

Increasing Focus on Advanced Research and Personalized Medicine

Technological advancements, including single-cell RNA sequencing and mass cytometry, are transforming IBD treatment. These technologies enable a deeper understanding of disease mechanisms, helping develop targeted therapies and personalized treatment approaches. Increasing collaborations between research institutions and pharmaceutical companies are accelerating innovation in the field.

Market Growth Drivers

Rising Prevalence of IBD

The increasing number of patients diagnosed with Crohn's disease and ulcerative colitis is a key driver of market growth. Genetic factors, lifestyle changes, and environmental triggers are contributing to the growing disease burden. Higher awareness and improved diagnostic capabilities are also increasing the number of patients undergoing treatment.

Strong Pipeline of Therapeutics

Pharmaceutical companies are actively investing in research and development to expand their product pipelines. With over 145 active clinical trials, many drugs are in advanced stages of development. The growing availability of biologics, TNF inhibitors, IL inhibitors, and JAK inhibitors is significantly improving treatment outcomes and driving market expansion.

Market Restraints

High Cost of Treatment

One of the major challenges in the market is the high cost of IBD therapies, particularly biologics. Treatment costs can range significantly per patient annually, limiting accessibility in developing regions. Additionally, limited reimbursement policies in emerging economies such as India and China further restrict market growth.

Market Segmentation Analysis

By Disease Indication

The market is segmented into Crohn's disease and ulcerative colitis. The Crohn's disease segment is expected to dominate with a 63.78% share in 2026, driven by increasing prevalence and treatment rates globally. The ulcerative colitis segment is also growing due to rising drug approvals and improved treatment accessibility.

By Route of Administration

Based on route of administration, the market is divided into oral and injectable drugs. The injectables segment dominated with a 77.58% share in 2026, primarily due to the widespread use of biologics administered via injections. Oral medications are gaining traction due to convenience and ease of use.

By Drug Class

The market includes TNF inhibitors, IL inhibitors, JAK inhibitors, anti-integrin, corticosteroids, and others. TNF inhibitors led the market with a 58.77% share in 2026, owing to their high efficacy in inducing and maintaining remission. JAK inhibitors are also gaining popularity due to their rapid onset of action.

By Distribution Channel

The market is segmented into hospital pharmacies and retail pharmacies. The hospital pharmacy segment dominated with a 95.36% share in 2026, supported by reimbursement policies and the need for specialized drug administration.

Regional Insights

North America

North America led the market with USD 12.13 billion in 2025 and is projected to reach USD 12.81 billion in 2026. Growth is driven by advanced biologic therapies, favorable reimbursement systems, and increasing disease prevalence.

Europe

Europe accounted for USD 9.69 billion in 2025, expected to reach USD 10.28 billion in 2026. The region benefits from strong regulatory support and availability of innovative therapies.

Asia Pacific

Asia Pacific held USD 5.81 billion in 2025 and is projected to reach USD 6.12 billion in 2026. Increasing awareness, improving healthcare infrastructure, and rising drug approvals are driving growth in the region.

Latin America and Middle East & Africa

Latin America reached USD 1.19 billion in 2025, while the Middle East & Africa accounted for USD 0.76 billion. Both regions are experiencing gradual growth due to rising healthcare investments and awareness.

Competitive Landscape

The market is consolidated, with major players including AbbVie Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Johnson & Johnson, Bristol-Myers Squibb, and Celltrion. These companies are focusing on product innovation, regulatory approvals, and strategic collaborations to strengthen their market position.

Conclusion

The global inflammatory bowel disease treatment market is set for steady growth, driven by rising disease prevalence, advancements in biologics, and increasing research activities. Although high treatment costs and limited reimbursement in emerging economies pose challenges, continuous innovation and expanding therapeutic options are expected to enhance patient outcomes. With the market projected to reach USD 41.64 billion by 2034, the IBD treatment industry will play a crucial role in addressing the growing global burden of chronic gastrointestinal diseases.

Segmentation By Disease Indication

  • Ulcerative Colitis
  • Crohn's Disease

By Route of Administration

  • Oral
  • Injectables

By Drug Class

  • IL Inhibitors
  • TNF Inhibitors
  • Anti-integrin
  • JAK Inhibitors
  • Corticosteroids
  • ASA Drugs
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy & Other

By Geography

  • North America (By Disease Indication, By Route of Administration, By Drug Class, By Distribution Channel, and By Country)
    • U.S. (By Disease Indication)
    • Canada (By Disease Indication)
  • Europe (By Disease Indication, By Route of Administration, By Drug Class, By Distribution Channel, and By Country)
    • U.K. (By Disease Indication)
    • Germany (By Disease Indication)
    • France (By Disease Indication)
    • Italy (By Disease Indication)
    • Spain (By Disease Indication)
    • Scandinavia (By Disease Indication)
    • Rest of Europe (By Disease Indication)
  • Asia Pacific (By Disease Indication, By Route of Administration, By Drug Class, By Distribution Channel, and By Country)
    • China (By Disease Indication)
    • Japan (By Disease Indication)
    • India (By Disease Indication)
    • Australia (By Disease Indication)
    • Southeast Asia (By Disease Indication)
    • Rest of Asia Pacific (By Disease Indication)
  • Latin America (By Disease Indication, By Route of Administration, By Drug Class, By Distribution Channel, and By Country)
    • Brazil (By Disease Indication)
    • Mexico (By Disease Indication)
    • Rest of Latin America (By Disease Indication)
  • Middle East & Africa (By Disease Indication, By Route of Administration, By Drug Class, By Distribution Channel, and By Country)
    • GCC (By Disease Indication)
    • South Africa (By Disease Indication)
    • Rest of MEA (By Disease Indication)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Crohn's Disease, By Key Regions/Countries, 2025
  • 4.2. Prevalence of Ulcerative Colitis, By Key Regions/Countries, 2025
  • 4.3. Average Length of Therapy for Inflammatory Bowel Disease
  • 4.4. Statistical Overview of Patients Undergoing Different Therapies
  • 4.5. Pricing and Margin Analysis
  • 4.6. New Product Launches, By Key Players
  • 4.7. Key Industry Developments - Mergers, Acquisitions, and Partnerships
  • 4.8. Pipeline Analysis, By Key Players
  • 4.9. COVID-19 Impact on the Market

5. Global Inflammatory Bowel Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.1.1. Ulcerative Colitis
    • 5.1.2. Crohn's Disease
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Injectables
  • 5.3. Market Analysis, Insights and Forecast - By Drug Class
    • 5.3.1. IL Inhibitors
    • 5.3.2. TNF Inhibitors
    • 5.3.3. Anti-integrin
    • 5.3.4. JAK Inhibitors
    • 5.3.5. Corticosteroids
    • 5.3.6. ASA Drugs
    • 5.3.7. Others
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacy
    • 5.4.2. Retail Pharmacy & Others
  • 5.5. Market Analysis, Insights and Forecast - By Geography
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Inflammatory Bowel Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Disease Indication
    • 6.1.1. Ulcerative Colitis
    • 6.1.2. Crohn's Disease
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Injectables
  • 6.3. Market Analysis, Insights and Forecast - By Drug Class
    • 6.3.1. IL Inhibitors
    • 6.3.2. TNF Inhibitors
    • 6.3.3. Anti-integrin
    • 6.3.4. JAK Inhibitors
    • 6.3.5. Corticosteroids
    • 6.3.6. ASA Drugs
    • 6.3.7. Others
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacy
    • 6.4.2. Retail Pharmacy & Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
      • 6.5.1.1. By Disease Indication
    • 6.5.2. Canada
      • 6.5.2.1. By Disease Indication

7. Europe Inflammatory Bowel Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Disease Indication
    • 7.1.1. Ulcerative Colitis
    • 7.1.2. Crohn's Disease
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Injectables
  • 7.3. Market Analysis, Insights and Forecast - By Drug Class
    • 7.3.1. IL Inhibitors
    • 7.3.2. TNF Inhibitors
    • 7.3.3. Anti-integrin
    • 7.3.4. JAK Inhibitors
    • 7.3.5. Corticosteroids
    • 7.3.6. ASA Drugs
    • 7.3.7. Others
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacy
    • 7.4.2. Retail Pharmacy & Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.5.1. U.K.
      • 7.5.1.1. By Disease Indication
    • 7.5.2. Germany
      • 7.5.2.1. By Disease Indication
    • 7.5.3. France
      • 7.5.3.1. By Disease Indication
    • 7.5.4. Spain
      • 7.5.4.1. By Disease Indication
    • 7.5.5. Italy
      • 7.5.5.1. By Disease Indication
    • 7.5.6. Scandinavia
      • 7.5.6.1. By Disease Indication
    • 7.5.7. Rest of Europe
      • 7.5.7.1. By Disease Indication

8. Asia Pacific Inflammatory Bowel Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Disease Indication
    • 8.1.1. Ulcerative Colitis
    • 8.1.2. Crohn's Disease
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Injectables
  • 8.3. Market Analysis, Insights and Forecast - By Drug Class
    • 8.3.1. IL Inhibitors
    • 8.3.2. TNF Inhibitors
    • 8.3.3. Anti-integrin
    • 8.3.4. JAK Inhibitors
    • 8.3.5. Corticosteroids
    • 8.3.6. ASA Drugs
    • 8.3.7. Others
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacy
    • 8.4.2. Retail Pharmacy & Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.5.1. Japan
      • 8.5.1.1. By Disease Indication
    • 8.5.2. China
      • 8.5.2.1. By Disease Indication
    • 8.5.3. India
      • 8.5.3.1. By Disease Indication
    • 8.5.4. Australia
      • 8.5.4.1. By Disease Indication
    • 8.5.5. Southeast Asia
      • 8.5.5.1. By Disease Indication
    • 8.5.6. Rest of Asia Pacific
      • 8.5.6.1. By Disease Indication

9. Latin America Inflammatory Bowel Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Disease Indication
    • 9.1.1. Ulcerative Colitis
    • 9.1.2. Crohn's Disease
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Injectables
  • 9.3. Market Analysis, Insights and Forecast - By Drug Class
    • 9.3.1. IL Inhibitors
    • 9.3.2. TNF Inhibitors
    • 9.3.3. Anti-integrin
    • 9.3.4. JAK Inhibitors
    • 9.3.5. Corticosteroids
    • 9.3.6. ASA Drugs
    • 9.3.7. Others
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacy
    • 9.4.2. Retail Pharmacy & Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.5.1. Brazil
      • 9.5.1.1. By Disease Indication
    • 9.5.2. Mexico
      • 9.5.2.1. By Disease Indication
    • 9.5.3. Rest of Latin America
      • 9.5.3.1. By Disease Indication

10. Middle East & Africa Inflammatory Bowel Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Disease Indication
    • 10.1.1. Ulcerative Colitis
    • 10.1.2. Crohn's Disease
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Injectables
  • 10.3. Market Analysis, Insights and Forecast - By Drug Class
    • 10.3.1. IL Inhibitors
    • 10.3.2. TNF Inhibitors
    • 10.3.3. Anti-integrin
    • 10.3.4. JAK Inhibitors
    • 10.3.5. Corticosteroids
    • 10.3.6. ASA Drugs
    • 10.3.7. Others
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacy
    • 10.4.2. Retail Pharmacy & Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.5.1. GCC Countries
      • 10.5.1.1. By Disease Indication
    • 10.5.2. South Africa
      • 10.5.2.1. By Disease Indication
    • 10.5.3. Rest of Middle East & Africa
      • 10.5.3.1. By Disease Indication

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Pfizer Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Product
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. CELLTRION INC.
      • 11.2.2.1. Overview
      • 11.2.2.2. Product
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Johnson & Johnson Services, Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Product
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. AbbVie Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Product
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Takeda Pharmaceutical Company Limited
      • 11.2.5.1. Overview
      • 11.2.5.2. Product
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. UCB S.A.
      • 11.2.6.1. Overview
      • 11.2.6.2. Product
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Bausch Health Companies Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Product
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Bristol-Myers Squibb Company
      • 11.2.8.1. Overview
      • 11.2.8.2. Product
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Eli Lilly and Company
      • 11.2.9.1. Overview
      • 11.2.9.2. Product
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Gilead Sciences
      • 11.2.10.1. Overview
      • 11.2.10.2. Product
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. EA Pharma Co., Ltd
      • 11.2.11.1. Overview
      • 11.2.11.2. Product
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 2: Global Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 3: Global Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034
  • Table 4: Global Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 5: Global Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Region, 2021-2034
  • Table 6: North America Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 7: North America Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 8: North America Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034
  • Table 9: North America Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 10: North America Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: U.S. Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 12: Canada Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 13: Europe Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 14: Europe Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 15: Europe Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034
  • Table 16: Europe Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 17: Europe Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 18: Germany Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 19: U.K. Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 20: France Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 21: Italy Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 22: Spain Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 23: Scandinavia Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 24: Rest of Europe Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 25: Asia Pacific Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 26: Asia Pacific Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 27: Asia Pacific Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034
  • Table 28: Asia Pacific Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 29: Asia Pacific Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 30: Japan Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 31: India Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 32: China Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 33: Australia Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 34: Southeast Asia Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 35: Rest of Asia Pacific Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 36: Latin America Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 37: Latin America Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 38: Latin America Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034
  • Table 39: Latin America Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 40: Latin America Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 41: Brazil Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 42: Mexico Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 43: Rest of Latin America Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 44: Middle East & Africa Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 45: Middle East & Africa Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 46: Middle East & Africa Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034
  • Table 47: Middle East & Africa Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 48: Middle East & Africa Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 49: GCC Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 50: South Africa Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 51: Rest of Middle East & Africa Inflammatory Bowel Disease Treatment Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034

List of Figures

  • Figure 1: Global Inflammatory Bowel Disease Treatment Market Revenue Breakdown (USD billion, %) By Region, 2025 & 2034
  • Figure 2: Global Inflammatory Bowel Disease Treatment Market Value Share (%), By Disease Indication, 2025 & 2034
  • Figure 3: Global Inflammatory Bowel Disease Treatment Market Value Share (%), By Route of Administration, 2025 & 2034
  • Figure 4: Global Inflammatory Bowel Disease Treatment Market Value Share (%), By Drug Class, 2025 & 2034
  • Figure 5: Global Inflammatory Bowel Disease Treatment Market Value Share (%), By Distribution Channel, 2025 & 2034
  • Figure 6: Global Inflammatory Bowel Disease Treatment Market Value (USD billion), By Region, 2025 & 2034
  • Figure 7: North America Inflammatory Bowel Disease Treatment Market Value (USD billion), By Disease Indication, 2025 & 2034
  • Figure 8: North America Inflammatory Bowel Disease Treatment Market Value Share (%), By Disease Indication, 2025
  • Figure 9: North America Inflammatory Bowel Disease Treatment Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 10: North America Inflammatory Bowel Disease Treatment Market Value Share (%), By Route of Administration, 2025
  • Figure 11: North America Inflammatory Bowel Disease Treatment Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 12: North America Inflammatory Bowel Disease Treatment Market Value Share (%), By Drug Class, 2025
  • Figure 13: North America Inflammatory Bowel Disease Treatment Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 14: North America Inflammatory Bowel Disease Treatment Market Value Share (%), By Distribution Channel, 2025
  • Figure 15: North America Inflammatory Bowel Disease Treatment Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Inflammatory Bowel Disease Treatment Market Value Share (%), By Country, 2025
  • Figure 17: Europe Inflammatory Bowel Disease Treatment Market Value (USD billion), By Disease Indication, 2025 & 2034
  • Figure 18: Europe Inflammatory Bowel Disease Treatment Market Value Share (%), By Disease Indication, 2025
  • Figure 19: Europe Inflammatory Bowel Disease Treatment Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 20: Europe Inflammatory Bowel Disease Treatment Market Value Share (%), By Route of Administration, 2025
  • Figure 21: Europe Inflammatory Bowel Disease Treatment Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 22: Europe Inflammatory Bowel Disease Treatment Market Value Share (%), By Drug Class, 2025
  • Figure 23: Europe Inflammatory Bowel Disease Treatment Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 24: Europe Inflammatory Bowel Disease Treatment Market Value Share (%), By Distribution Channel, 2025
  • Figure 25: Europe Inflammatory Bowel Disease Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Inflammatory Bowel Disease Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Inflammatory Bowel Disease Treatment Market Value (USD billion), By Disease Indication, 2025 & 2034
  • Figure 28: Asia Pacific Inflammatory Bowel Disease Treatment Market Value Share (%), By Disease Indication, 2025
  • Figure 29: Asia Pacific Inflammatory Bowel Disease Treatment Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 30: Asia Pacific Inflammatory Bowel Disease Treatment Market Value Share (%), By Route of Administration, 2025
  • Figure 31: Asia Pacific Inflammatory Bowel Disease Treatment Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 32: Asia Pacific Inflammatory Bowel Disease Treatment Market Value Share (%), By Drug Class, 2025
  • Figure 33: Asia Pacific Inflammatory Bowel Disease Treatment Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Inflammatory Bowel Disease Treatment Market Value Share (%), By Distribution Channel, 2025
  • Figure 35: Asia Pacific Inflammatory Bowel Disease Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Inflammatory Bowel Disease Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Inflammatory Bowel Disease Treatment Market Value (USD billion), By Disease Indication, 2025 & 2034
  • Figure 38: Latin America Inflammatory Bowel Disease Treatment Market Value Share (%), By Disease Indication, 2025
  • Figure 39: Latin America Inflammatory Bowel Disease Treatment Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 40: Latin America Inflammatory Bowel Disease Treatment Market Value Share (%), By Route of Administration, 2025
  • Figure 41: Latin America Inflammatory Bowel Disease Treatment Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 42: Latin America Inflammatory Bowel Disease Treatment Market Value Share (%), By Drug Class, 2025
  • Figure 43: Latin America Inflammatory Bowel Disease Treatment Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Inflammatory Bowel Disease Treatment Market Value Share (%), By Distribution Channel, 2025
  • Figure 45: Latin America Inflammatory Bowel Disease Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Inflammatory Bowel Disease Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Inflammatory Bowel Disease Treatment Market Value (USD billion), By Disease Indication, 2025 & 2034
  • Figure 48: Middle East & Africa Inflammatory Bowel Disease Treatment Market Value Share (%), By Disease Indication, 2025
  • Figure 49: Middle East & Africa Inflammatory Bowel Disease Treatment Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 50: Middle East & Africa Inflammatory Bowel Disease Treatment Market Value Share (%), By Route of Administration, 2025
  • Figure 51: Middle East & Africa Inflammatory Bowel Disease Treatment Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 52: Middle East & Africa Inflammatory Bowel Disease Treatment Market Value Share (%), By Drug Class, 2025
  • Figure 53: Middle East & Africa Inflammatory Bowel Disease Treatment Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Inflammatory Bowel Disease Treatment Market Value Share (%), By Distribution Channel, 2025
  • Figure 55: Middle East & Africa Inflammatory Bowel Disease Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Inflammatory Bowel Disease Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Inflammatory Bowel Disease Treatment Market Share (%), By Company, 2025